(a) The following documents are filed as part of this report:
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 274) | F-2 |
|---|
| Consolidated Balance Sheets – December 31, 2023 and 2022 | F-3 |
|---|
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
|---|
| Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-5 |
|---|
| Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended December 31, 2023 and 2022 | F-6 |
|---|
| Consolidated Statements of Cash Flow for the Years Ended December 31, 2023 and 2022 | F-7 |
|---|
| Notes to Consolidated Financial Statements | F-8 |
|---|
| (2) | Financial Statement Schedules |
All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.
The following exhibits are filed herewith or incorporated by reference herein:
| Exhibit No. | Description |
| 3.1(a) | Certificate of Conversion (Texas) |
| 3.2(a) | Certificate of Conversion (Delaware) |
| 3.3(a) | Certificate of Incorporation |
| 3.4(b) | Certificate of Amendment to Certificate of Incorporation |
| 3.5(b) | Amended and Restated Certificate of Incorporation |
| 3.1.(vi)(a) | By-laws |
| 4.1(a) | Form of Warrant (2019) |
| 4.2(c) | Form of Amendment to Series A Preferred Stock Warrant |
| 4.3(i) | Form of Underwriters’ Warrant (2020) |
| 4.4(d) | Specimen Stock Certificate evidencing shares of common stock |
| 4.5(k) | Description of Capital Stock |
| 10.1(l) | Second Amended and Restated 2018 Equity Incentive Plan dated October 20, 2022 |
| 10.2(m) | Amendment to Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan |
| 10.3+(a) | Employment Agreement dated July 23, 2018 with Panna Sharma |
| 10.4+(f) | Amendment to Employment Agreement dated May 18, 2020 with Panna Sharma |
| 10.5+(c) | Employment Agreement dated May 18, 2020 with David Margrave |
| 10.6* | Amendment to Employment Agreement with Kishor Bhatia dated December 28, 2023 |
| 10.7* | Amendment to Employment Agreement with David Margrave dated December 28, 2023 |
| 10.8+(a) | Form of Indemnification Agreement |
| 10.9(a) | Amended and Restated Investors’ Rights Agreement |
| 10.10#(a) | Technology License Agreement dated January 15, 2015, with AF Chemicals, LLC |
| 10.11#(a) | Assignment Agreement dated as of January 5, 2018 with BioNumerik Pharmaceuticals, Inc. |
| 10.12#(a) | Addendum to Technology License Agreement dated February 8, 2016, with AF Chemicals, LLC |
| 10.13+(c) | Employment Agreement dated May 18, 2020 with Kishor G Bhatia |
| 10.14(g) | API Services Project Agreement dated July 10, 2020 with Patheon API Service |
| 10.15#(h) | Second Addendum to Technology License Agreement dated December 30, 2020 with AF Chemicals, LLC |
| 21.1(l) | List of Subsidiaries |
| 23.1* | Consent of EisnerAmper LLP, independent registered public accounting firm |
|---|
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|---|
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|---|
| 32.1** | Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|---|
| 97.1* | Lantern Pharma Inc. Executive Officer Clawback Policy |
|---|
| 101.INS* | Inline XBRL Instance Document |
|---|
| 101.SCH* | Inline XBRL Taxonomy Extension Schema |
|---|
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase |
|---|
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase |
|---|
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase |
|---|
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase |
|---|
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
|---|
| (a) | Incorporated by reference from the Registration Statement on Form S-1 filed April 16, 2020. |
|---|
| (b) | Incorporated by reference from Current Report on Form 8-K filed June 17, 2020. |
|---|
| (c) | Incorporated by reference from the Registration Statement on Form S-1/A filed May 19, 2020. |
|---|
| (d) | Incorporated by reference from the Registration Statement on Form S-1/A filed May 12, 2020. |
|---|
| (e) | Incorporated by reference from Current Report on Form 8-K filed August 21, 2020. |
|---|
| (f) | Incorporated by reference from the Registration Statement on Form S-1/A filed June 8, 2020. |
|---|
| (g) | Incorporated by reference from Quarterly Report on Form 10-Q for the period ending September 30, 2020. |
|---|
| (h) | Incorporated by reference from the Registration Statement on Form S-1 filed January 8, 2021. |
|---|
| (i) | Incorporated by reference from Exhibit 1.1 of the Registration Statement on Form S-1/A filed May 19, 2020. |
|---|
| (m) | Incorporated by reference from Exhibit A to Registrant’s Definitive Proxy Statement filed April 28, 2023. |
|---|
| + | Indicates a management control or any compensatory plan, contract or arrangement. |
|---|
| # | Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark) because the identified confidential portions (i) are not material and (ii) are of the type that the Registrant treats as private and confidential. |
|---|
| ** | Furnished with this report |
|---|
